DNER and carcinoma: The safety profile of BI 894999 was consistent with other BET inhibitors, including myelosuppression, hematological, gastrointestinal, and skin disorders, fatigue, and non‐hematological laboratory abnormalities, although the efficacy in NUT carcinoma was not disclosed.35